GenVec and Varian extend collaboration agreement:
This article was originally published in Clinica
Executive Summary
GenVec and Varian Medical Systems' Biosynergy business unit are extending a collaborative agreement, which combines gene therapy products with targeted radiation therapy for the treatment of cancer, after promising preclinical results. The agreement, which dates from 1998, will now extend through 2004. Varian has primary responsibility for the development of equipment and software for the delivery of targeted radiation therapy, while GenVec has responsibility for developing gene therapy products.